A Phase I/II trial of glofitamab monotherapy in R/R MCL

Glofitamab and obinutuzumab in r/r MCLПодробнее

Glofitamab step-up dosing in R/R MCLПодробнее

NP30179: Glofitamab monotherapy in R/R NHLПодробнее

Phase II trial of acalabrutinib, lenalidomide and rituximab in patients with MCLПодробнее

Glofitamab: a valuable agent for the treatment of patients with R/R mantle cell lymphomaПодробнее

Michael Dickinson, MBBS, DMedSc, on a Phase II Trial of Glofitamab in DLBCLПодробнее

Phase II study of glofitamab in patients with R/R LBCLПодробнее

Update on Phase I/II study of glofitamab monotherapy in R/R MCLПодробнее

GLOBRYTE: investigating glofitamab monotherapy in patients with R/R MCLПодробнее

Highlights on first-line treatment of Mantle Cell Lymphoma: Primary results from SHINEПодробнее

Updates on the Phase I/II BRUIN study and the role of pirtobrutinib in MCLПодробнее

The STARGLO trial: glofitamab in combination with gemcitabine and oxaliplatin in R/R DLBCLПодробнее

Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in R/R FLПодробнее

Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphomaПодробнее

Preliminary results from NP40126: Glofitamab and R-CHOP in NHLПодробнее

Results from a Phase I/II trial of pirtobrutinib and LV20.19 for patients with R/R lymphomasПодробнее

Acalabrutinib monotherapy in R/R MCL: extended follow-up resultsПодробнее

Phase I/II study of zilovertamab and ibrutinib in MCL and CLLПодробнее

Hot updates in R/R MCL at ASH 2022: data on pirtobrutinib, glofitamab & zilovertamabПодробнее